JeffreyE.LeeMD
General Surgery • Houston, TXSurgical Oncology (Other than Breast)
Professor of Surgery, University Tex Houston
Dr. Lee is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161
Summary
- Dr. Jeff Lee serves as the Chief Medical Executive ad interim, and concurrently as Chief Cancer Network Officer at The University of Texas MD Anderson Cancer Center. Dr. Lee is a Professor in the Department of Surgical Oncology, and he holds the Irving and Nadine Mansfield and Robert David Levitt Cancer Research Chair. Dr. Lee received his bachelor’s degree from Dartmouth College and his medical degree from Stanford University School of Medicine; he completed an internship and residency in surgery and a research fellowship in tumor immunology at Stanford, followed by a clinical fellowship in surgical oncology at MD Anderson. He joined the faculty at MD Anderson following completion of his surgical oncology fellowship in 1993. Dr. Lee previously served as Medical Director of the Ben Love/El Paso Corporation Melanoma and Skin Center (1997-2010), as Chair of the Department of Surgical Oncology (2010-2021), as Vice President, Medical and Academic Affairs, Cancer Network (2019-2022), and as Vice President, Clinical Operations Strategy Execution and Institutional Preparedness & Deputy Chief Operating Officer (2022-2024) at MD Anderson. He was appointed Chief Medical Executive ad interim September 1, 2024. Dr. Lee has had a three-decade peer-review funded collaborative laboratory research program focused on melanoma genetics, melanoma immune and inflammatory biomarkers, and the development of novel antibody-based therapeutics for melanoma and other cancers. Dr. Lee’s areas of clinical interest include the management of borderline resectable pancreatic cancer, vascular resection in pancreatic surgery, multiple endocrine neoplasia, adrenal cortical cancer, neoadjuvant therapy for pancreas and adrenal cancer, minimally invasive adrenal surgery, and surgery for metastatic melanoma.
Education & Training
University of Texas M D Anderson Cancer CenterFellowship, Complex General Surgical Oncology, 1991 - 1993
Stanford Health Care-Sponsored Stanford UniversityResidency, Surgery, 1989 - 1991- Stanford Health Care-Sponsored Stanford UniversityResidency, Surgery, 1984 - 1987
Stanford University School of MedicineClass of 1984
Certifications & Licensure
CA State Medical License 1985 - Present
FL State Medical License 2021 - Present
GA State Medical License 2022 - 2026
AL State Medical License 2022 - 2025
AZ State Medical License 2022 - 2025
LA State Medical License 2022 - 2025
MS State Medical License 2022 - 2025
American Board of Surgery Surgery- Join now to see all
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2002-2014
- Top Doctors:SE Texas Castle Connolly, 2013
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
- Join now to see all
Clinical Trials
- Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery Start of enrollment: 2010 Apr 12
Publications & Presentations
PubMed
- Total Venous Control and Vein-to-the-Right Superior Mesenteric Artery Approach in Robotic Pancreatoduodenectomy.Madeline B Torres, Jessica E Maxwell, Rebecca A Snyder, Hop S Tran Cao, Michael P Kim
Annals of Surgical Oncology. 2024-12-01 - DNA Methylation Classes of Stage II and III Primary Melanomas and Their Clinical and Prognostic Significance.Kathleen Conway, Sharon N Edmiston, Amanda Vondras, Allison Reiner, David L Corcoran
JCO Precision Oncology. 2024-11-01 - Postoperative Global Period Cost Reduction Using 3 Successive Risk-Stratified Pancreatectomy Clinical Pathways.Ahad Azimuddin, Ching-Wei D Tzeng, Laura R Prakash, Morgan L Bruno, Elsa M Arvide
Journal of the American College of Surgeons. 2024-04-01
Journal Articles
- Response and Survival Associated with First-Line FOLFIRINOX vs Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal AdenocarcinomaShubham Pant, Milind Javle, Naruhiko Ikoma, Ching-Wei Tzeng, Jeffrey E Lee, JAMA Surgery
- Middle Hepatic Vein Roadmap for a Safe Laparoscopic Right HepatectomyJose M Soliz, Claudius Conrad, Jeffrey E Lee, Annals of Surgical Oncology
- Author Correction: Neoadjuvant Immune Checkpoint Blockade in High-Risk Resectable MelanomaJanice N Cormier, Ehab Hanna, Padmanee Sharma, Jennifer A Wargo, Isabella C Glitza, Sapna P Patel, Adi Diab, Jeffrey E Lee, Richard Royal, Randal Weber, Patrick Hwu, J..., Nature
- Join now to see all
Authored Content
- Response and Survival Associated with First-Line FOLFIRINOX vs Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal AdenocarcinomaJuly 2020
- Response and Survival Associated with First-Line FOLFIRINOX vs Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal AdenocarcinomaJuly 2020
Press Mentions
MD Anderson Research Highlights for March 27, 2025March 27th, 2025- MD Anderson Names Jeffrey E. Lee, M.D., Chief Medical ExecutiveMarch 26th, 2025
Best of the Best in Care: Meet Houston's Top Doctors 2016October 21st, 2016
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
